Dr. Reddy's Laboratories Launches Chlorthalidone Tablets, USP in the US Market
30 November 2018 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has lauched Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton (chlorthalidone) Tablets, in the US market following approval by the US Food and Drug Administration (USFDA), the company said.

The Hygroton brand and generic had US sales of approximately USD 122m MAT for the most recent twelve months ending in September 2018 according to IMS Health.

Dr. Reddy's Chlorthalidone Tablets, USP are available in 25 mg tablets in the bottle-count sizes of 100 and 1000, and 50 mg tablets in the bottle-count size of 100.